When you receive your medication, you know exactly what's in it and where it came from
In comparison, tirzepatide has not been FDA-approved for this purpose yet
This biased agonism refers to the fact that tirzepatide selectively engages cAMP signaling over -arrestin recruitment at the GLP-1R, which may augment cellular response via beneficial impact on GLP-1R cell surface trafficking, leading to increased cell surface expression
(2019) on NAC in patients with non-alcoholic fatty liver disease (NAFLD) showed that while NAC helped reduce oxidative stress markers, it failed to significantly improve inflammatory cytokine levels or liver function in the long term, highlighting NACs gap in managing inflammation
Notably, all of this reduction was attributable to fat mass, while lean mass increased by 2.5%
Time-varying hazard ratios and KaplanMeier curves captured temporal treatment dynamics